Open-Label Study to Assess the Long-term Safety and Efficacy of Momelotinib in Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Gilead Sciences, Inc.
Start Date
December 14, 2016
End Date
October 17, 2017
Administered By
Duke Cancer Institute
Awarded By
Gilead Sciences, Inc.
Start Date
December 14, 2016
End Date
October 17, 2017